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Case presentation 
A 53-year-old white man was readmitted to the hospital for recurrent 
dyspnea and edema due to dilated cardiomyopathy. He had been 
discharged from the hospital 4 weeks previously with minimal edema. 
His medications at that time included enalapril, 5 mg/day; digoxin, 0.25 
mg/day; and furosemide, 80 mg twice daily. Between the two hospital-
izations, he had noted gradually increasing orthopnea, nocturia, short-
ness of breath on exertion, and peripheral edema. He claimed that he 
was adhering to dietary sodium restriction and that he was taking his 
medications faithfully. He had had no episodes of chest pain or 
diaphoresis. 
Physical examination revealed a well-developed man in mild respira-
tory distress. Vital signs showed a blood pressure of 115/85 mm Hg; 
pulse rate, 96 b<;ats/min and regular; and a respiratory rate of 24/min. 
His weight was 84 kg, 10 kg more than his weight at discharge. Positive 
physical findings included an estimated jugular venous pressure greater 
than 15 cm H20, an S3 gallop, a 2/6 holosystolic murmur at the apex, 
wet rales at the bases, and 4+ peripheral edema extending to the 
mid-thigh. Laboratory findings were unremarkable except for a BUN of 
47 mg/dl and plasma creatinine of 2.1 mg/dl. 
The patient initialiy was given furosemide in single oral doses as high 
as 160 mg. He had little response to this regimen, but he did respond 
well to 120 mg given intravenously. The diuresis lasted only 4 hours, 
however, and the patient was oliguric for the remainder of the day. As 
a result, he was given the same dose twice daily and gradually lost most 
of his edema without showing any evidence of hypoperfusion, such as 
a rise in the BUN. The patient's medication was changed to furosemide, 
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120 mg orally twice daily, and he remained under good control in the 
hospital. He was discharged on this regimen with his symptoms much 
improved. At home, he noted that his exercise tolerance had improved 
and that he was able to resume some of his normal daily activities. 
Within one week, however, the edema recurred. 
Discussion 
DR. BURTON D. ROSE (Director, Clinical Nephrology, 
Brigham and Women's Hospital, and Associate Professor of 
Medicine, Harvard Medical School, Boston, Massachusetts): 
Diuretics have been widely used for more than 40 years, 
particularly in the treatment of edema and hypertension. Their 
major renal effect is to increase the excretion of sodium and 
water. Our understanding of the mechanisms by which this 
saluresis occurs has evolved relatively slowly. Initial studies in 
the 1950s and 1960s elucidated the site of action of the different 
classes of diuretics by determining the effects on free water 
clearance and reabsorption (that is, diluting and concentrating 
ability) and on potassium excretion, recognizing that the latter 
is in part a function of the delivery of sodium and water to the 
potassium secretory sites in the distal nephron. The results of 
these studies can be summarized as follows [1, 2]: 
(1) The thiazides were thought to act in the cortical distal 
tubule because they increased potassium excretion (by increas-
ing distal sodium and water delivery), and they impaired 
dilution but not concentration (which is primarily a medullary 
function). 
(2) The carbonic anhydrase inhibitors, such ,as acetazola-
mide, were thought to inhibit bicarbonate reabsorption in the 
proximal tubule because they increased free water clearance 
and reabsorption (by augmenting sodium and water delivery out 
of the proximal tubule) and increased potassium (and bicarbon-
ate) excretion. 
(3) Furosemide arid ethacrynic acid were thought to act in the 
medullary aspect of the ascending limb of the loop of Henle 
because they inhibited both concentration and dilution, and 
they increased potassium excretion. 
(4) The potassium-sparing diuretics, such as spironolactone, 
were thought to act at the potassium secretory site in the 
collecting tubules because they diminished potassium excre-
tion. 
These indirect observations were confirmed by micropunc-
ture experiments and by perfusion of isolated tubule segments 
[3]. What remained unclear, however, was what determined the 
specific site of action of the different diuretics at a cellular level. 
The answer to this question has come from studies that clarified 
the cellular transport mechanisms by which sodium is reab-
sorbed. In particular, each nephron segment possesses a 
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Table 1. Mechanisms of sodium transport throughout the nephron 
Major mechanisms of Major factors regulating 
sodium transport 
Diuretics acting at this 
site Tubule segment luminal sodium entry 
---------------------------------------------
--------------------
Proximal tubule 50 to 55 Na+-H+ exchange and 
cotransport with 
glucose, phosphate, 
amino acids, and 
other organic 
solutes 
Angiotensin II, 
norepinephrine, 
dopamine, glomerular 
filtration rate, 
peritubular capillary 
hemodynamics 
Acetazolamide 
Loop of Henle 
Distal tubule 
Collecting tubules 
35 to 40 
5 to 8 
2 to 3 
Na+-K+-2Cl-
cotransport 
Na+-Cl- cotransport 
Na+ channels 
relatively characteristic variety of transport proteins or chan-
nels by which filtered sodium enters the cells. These transport 
systems are inhibited only by certain diuretics, and it is this 
relationship that determines the diuretic's site of action (Table 
1). In comparison, osmotic diuretics, which I will not cover in 
this discusssion, act via their effects on tubular fluid composi-
tion and renal perfusion, not via interaction with specific 
transporters [4]. 
In the initial part of this discussion, I will review the transport 
properties of the several nephron segments, with emphasis on 
the handling of sodium and chloride. At each step, basic renal 
physiology will be examined from the clinician's viewpoint. 
Emphasis also will be placed on the problems associated with 
diuretic therapy, some of which are illustrated by the patient 
presented today: relative resistance to oral therapy when mark-
edly fluid overloaded; the requirement for mUltiple daily doses 
of a loop diuretic; and, despite a good response in the hospital, 
recurrent fluid retention in the outpatient setting without appar-
ent worsening of cardiac function. 
Overview of renal function 
Filtered sodium is reabsorbed throughout the nephron; less 
than 1 % is excreted in the urine in normal individuals ingesting 
a typical Western diet. Approximately 50% to 55% is reab-
sorbed in the proximal tubule, 35% to 40% in the loop of Henle, 
5% to 8% in the distal tubule and adjacent connecting segment, 
and 2% to 3% in the collecting tubules (Table 1). Transcellular 
sodium reabsorption requires transporters or channels in the 
luminal and basolateral membranes because charged ions can-
not freely pass through the lipid bilayer. The same two basic 
steps occur in each of the nephron segments; filtered sodium 
enters the cells across the luminal membrane and is subse-
quently actively transported out of the cell by the basolateral 
Na+-K+-ATPase pump (Fig. 1) [5]. 
In addition to its direct effect on sodium transport, the 
Na+-K+-ATPase pump has two other important actions. First, 
the extrusion of sodium from the cell maintains the cell sodium 
concentration at a low level, ranging between 10 and 30 
mEq/liter [6]. Second, by removing cell cations, the pump is 
responsible for generating an electrical potential that maintains 
the cell interior negative. This effect is related both to the 3:2 
stoichiometry of the pump (with more sodium leaving than 
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ethacrynic acid 
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chlorthalidone 
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- + 
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Fig. 1. General model for tubular reabsorption. Filtered Na+ enters 
the tubular cell via a transmembrane carrier (that may also transport 
another solute, X) or channel in the luminal membrane; it is then 
actively transported out of the cell into the peritubular interstitium by 
the Na+-K+-ATPase pump in the basolateral membrane. This pump 
also maintains the cell sodium concentration at a low level and creates 
a cell interior negative potential, resulting in part from diffusion of 
potassium back out of the cell. These two effects create a favorable 
electrochemical gradient that allows passive sodium entry into the cell 
in all nephron segments. 
potassium entering) and to the diffusion of potassium out of the 
cell through potassium channels in the basolateral membrane. 
The combination of the low cell sodium concentration and the 
negative electrical potential results in a favorable gradient 
throughout the nephron for passive sodium entry across the 
luminal membrane. Furthermore, the active reabsorption or 
secretion of many other substances (such as glucose, phos-
phate, and hydrogen in the proximal tubule) is accomplished by 
linkage to sodium, rather than necessitating separate energy-
requiring processes (Fig. 2a) [7-10]. Filtered solutes that enter 
the cell across the luminal membrane are returned to the 
systemic circulation across the basolateral membrane, again via 
specific transporters or channels [11]. For the sake of simplic-
ity, the following discussion will emphasize only the luminal 
entry mechanisms, because these are the transport mechanisms 
that are affected by diuretic therapy. 
338 Nephrology Forum: Diuretics 
Proximal tubule 
Glucose 
Phosphate --""T"'--. 
Amino acids 
HC03 + W 
(filtered) (secreted) 
a 
Loop of Henle 
Na+--7.-"""" .... 
K+ 
2CI-·-"""'r""-.... 
b 
Distal tubule 
c 
For this transepithelial transport system to function appro-
priately, membrane polarity must be maintained such that the 
transporters, channels, and Na + -K + -ATPase pumps are lo-
cated correctly. How correct localization occurs is incom-
pletely understood, but specific anchoring sequences in some 
transport proteins might play an important role in their ihsertion 
into the luminal membrane [12]. On the other hand, attachment 
to specific cytoskeletal proteins such as ankyrin may determine 
the basolateral location of the Na+-K+-ATPase pump [13]. 
Lateral movement of transport proteins between the luminal 
and basolateral membranes is prevented by the tight junction 
[14]. 
Proximal tubule 
Basic transport processes. As I noted before, the proximal 
tubule reabsorbs 50% to 55% of the filtered sodium and water. 
It also reabsorbs about 90% of the filtered bicarbonate (via 
hydrogen secretion), almost all of the filtered glucose, phos-
phate, amino acids, citrate, and other organic solutes, and it 
secretes a variety of organic anions (including most diuretics) 
and cations (Fig. 2a) [15]. Most of these processes work via 
coupled transport with sodium; occupation of all the sites on the 
transport protein (such as the sodium and glucose binding sites 
on the sodium-glucose cotransporter) presumably induces a 
physical change in the protein that favors solute movement 
("translocation") across the membrane. 
Sodium-glucose cotransport, for example, is responsible for 
the reabsorption of filtered glucose [7, 8]. Interestingly, dif-
ferent proximal segments possess cotransporters with different 
characteristics [8]. The S. and S2 segments have a high-
Collecting tubule 
- + 
d 
Fig. 2. Schematic representation of the major 
mechanisms of passive sodium entry across 
the luminal membrane in the different 
nephron segments. The transepithelial 
potential difference also is noted for those 
segments in which it is an important 
determinant of ion transport: the loop of 
Henle and the collecting tubule. See text for 
details. 
capacity, low-affinity transporter (with a 1 Na+:l glucose 
binding ratio) that is responsible for most of glucose reabsorp-
tion. As a result, relatively little glucose is delivered to the S3 
segment. To reclaim this glucose, the carrier at this site has a 
higher affinity and a 2 Na+:l glucose binding ratio. Thus, the 
combined effect of the inward movement of two sodium ions is 
used to drive the uphill transport of glucose. 
From the viewpoint of total proximal reabsorption, however, 
the Na+ -H+ exchanger (or antiporter) is of primary importance. 
In addition to being responsible for most of proximal bicarbon-
ate reabsorption [10], this transport system also creates the 
gradient that allows approximately 45% to 50% of the filtered 
chloride to be reabsorbed [16, 17]. 
The mechanism responsible for at least part of transcellular 
chloride reabsorption is illustrated in Figure 2a. Chloride move-
ment across the luminal membrane appears to occur by a 
luminal chloride-anion exchanger [16, 18]. Surprisingly, an 
anion that appears to be important in chloride reabsorption is 
formate. Although formate normally is present in the proximal 
tubular fluid in a concentration of less than 1.0 mEq/liter, it can 
promote chloride transport because it is recycled across the 
luminal membrane. Filtered formate initially combines with 
hydrogen secreted by the Na + -H+ antiporter to form formic 
acid. The latter is lipid-soluble and therefore can diffuse into the 
cell (which is relatively alkaline in comparison to the lumen), 
where it dissociates into hydrogen and formate ions. Both of 
these ions then return to the lumen, the former via the Na + -H+ 
exchanger and the latter via a chloride-formate exchanger. The 
net effect is recycling of hydrogen and formate and the reab-
sorption of sodium and chloride. The quantitative role of 
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formate is uncertain: other anion exchangers, such as chloride-
hydroxyl and chloride-oxalate, are also thought to contribute to 
proximal chloride reabsorption [16, 19]. The reabsorbed sodium 
is returned to the peritubular interstitium by the Na+-K+-
ATPase pump, whereas chloride exits the cell primarily via a 
K + -Cl- cotransporter in the basolateral membrane, the energy 
for which is provided by the high cell potassium concentration 
[20]. 
Approximately one-third of proximal chloride reabsorption 
(primarily in the outer cortical nephrons) is passive and occurs 
via a mechanism that is again linked in part to Na + -H+ 
exchange [15, 16, 21]. The early proximal tubule reabsorbs most 
of the filtered bicarbonate, glucose, and amino acids, but a 
lesser fraction of chloride. Water is reabsorbed down the 
osmotic gradient created by solute reabsorption; this removal of 
water results in an elevation in the tubular fluid chloride 
concentration above that in the plasma and lateral intercellular 
space between the cells. Because the tight junction is more 
permeable to chloride than it is to bicarbonate [22], chloride is 
passively reabsorbed by the paracellular route across the tight 
junction, in part down the favorable chloride gradient between 
the lumen and interstitium and in part by solvent drag, following 
the reabsorption of water [IS, 23]. That the tight junction has a 
lower permeability to bicarbonate than to chloride results in the 
intercellular space having a higher effective osmolality than the 
lumen, where the concentration of chloride is high and that of 
bicarbonate is low [23]. The resulting gradient is sufficient to 
drive osmotic water reabsorption across the tight junction. 
To summarize, the luminal Na+ -H+ exchanger plays a major 
role in bUlk transport in the proximal tubule, directly reabsorb-
ing bicarbonate and indirectly creating the gradients that facil-
itate both active and passive chloride transport. In experimental 
animals, inhibition of the proximal Na + -H + exchanger inhibits 
almost all of transcellular chloride transport [17] . It is not 
surprising, therefore, that angiotensin II and norepinephrine, 
which stimulate Na + -H+ antiporter activity, increase the prox-
imal reabsorption of sodium, chloride, and water [15, 24] . 
(These hormones also promote proximal reabsorption by their 
effects on peritubular capillary hemodynamics [15]). Thus, 
activation of the renin-angiotensin and sympathetic nervous 
systems by, for example, diuretic-induced depletion of the 
effective extracellular volume helps restore normal tissue per-
fusion by limiting further urinary sodium excretion. 
The increase in Na + -H+ exchange induced by angiotensin II 
appears to be mediated by inhibition of adenylate cyclase, 
perhaps via activation of G j , the inhibitory guanine regulatory 
protein [24]. The net effect is diminution of the basal inhibitory 
effect of cyclic AMP on the Na+-H+ exchanger, thereby 
increasing its activity. Dopamine, on the other hand, reduces 
proximal sodium reabsorption primarily by decreasing the 
activity of the basolateral Na+-K+-ATPase pump [25]. Local 
dopamine release might be stimulated by atrial natriuretic 
peptide (ANP), and may account for a decrease in proximal 
transport induced by ANP [26]. The importance of the proximal 
tubule in the natriuretic response to ANP remains controver-
sial , however. 
Tubular secretion. The proximal tubule, particularly the S2 
segment , performs another function that has important impli-
cations for diuretic therapy: it secretes organic anions (for 
example, urate and a variety of drugs including thiazides, loop 
Tubular 
lumen 
Proximal tubular cell 
oc· 
Peritubular 
capillary 
oc· 
Fig. 3. Schematic model for the secretion of an organic cation (OC+) 
in the proximal tubule. Entry into the cell across the basolateral 
membrane occurs at least in part by passive, carrier-mediated diffusion 
down favorable concentration and electrical gradients (cell interior 
negative and low OC + concentration) . Secretion into the lumen across 
the luminal membrane appears to occur via H + -OC+ exchangers that 
are driven by the inward hydrogen gradient created by the Na + -H+ 
antiporter. (From Ref. \5.) 
diuretics, most penicillins, and cephalosporins) and organic 
cations (such as creatinine, amiloride, triamterene, cimetidine, 
and trimethoprim) [15, 27 , 28]. The relatively nonspecific nature 
of these secretory pathways and their ability to secrete foreign 
substances make them well adapted for a major role in the 
excretion of hydrophilic drugs and chemicals. These pathways 
are particularly important , because many of the drugs secreted 
by them are highly protein bound and therefore cannot enter the 
urine by glomerular filtration. Although albumin binding of 
these drugs limits their filtration, it promotes proximal secretion 
in two ways. First, the rate of delivery to the kidney is 
maximized because protein-bound compounds are largely re-
stricted to the vascular space, with limited movement across 
the peripheral capillary wall into the interstitium. Second , 
albumin , via an unknown mechanism, seems to be required for 
optimal secretion of organic anions (but apparently not for 
secretion of organic cations) [29, 30]. 
The energy for these secretory processes is again supplied 
indirectly by the Na+-K+-ATPase pump and the favorable 
electrochemical gradient for Na + entry into the cell. Figure 3 
illustrates the proposed model for the secretion of at least some 
organic cations [15, 28]. Cell entry across the basolateral 
membrane occurs at least in part by passive, carrier-mediated 
diffusion down favorable electrical (cell interior negative as in 
Fig. 1) and chemical (low organic cation concentration) gradi-
ents . Also, an active secretory pump might playa contributory 
role . Subsequent secretion into the tubular lumen appears to 
occur in parallel with the Na + -H+ exchanger. The rise in 
tubular fluid hydrogen ion concentration allows secretion of 
organic cations to be linked to the favorable inward gradient for 
hydrogen ion by different H + -cation exchangers [28]. (It is 
possible that this process actually represents cation-hydroxyl 
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cotransport, in which the energy is provided by the higher 
hydroxyl ion concentration in the cell.) 
The mechanism of organic anion secretion is not as well 
understood [15, 27]. Anion exchangers at both the basolateral 
and luminal membranes probably play an essential role. At the 
basolateral membrane, citric acid cycle intermediates (such as 
2-oxoglutarate and succinate) may enter the cell by cotransport 
with sodium down the favorable gradient for sodium entry [27]. 
The accumulation of the citric acid cycle intermediates within 
the cell then can provide the energy for organic anion uptake by 
an intermediate-organic anion exchanger. Subsequent secretion 
of the organic anion into the lumen may occur by carrier-
mediated diffusion (driven both by the favorable concentration 
gradient and cell-interior negativity) or in exchange for a 
luminal anion such as chloride. Characterization of these prox-
imal transport processes has helped us understand the mecha-
nisms by which carbonic anhydrase inhibitors act as diuretic 
agents and the mechanisms by which most diuretics enter the 
tubular lumen. 
Carbonic anhydrase inhibitors. Carbonic anhydrase, both in 
the cell and in the brush border of the luminal membrane, 
increases net Na + -H+ exchange [31, 32]. Within the cell, water 
is in equilibrium with free hydrogen and hydroxyl ions; car-
bonic anhydrase favors the formation of bicarbonate from 
carbon dioxide and hydroxyl ions, thereby increasing the 
availability of free hydrogen ions for secretion. On the other 
hand, carbonic anhydrase in the luminal membrane promotes 
the dissociation of luminal carbonic acid (formed from the 
combination of secreted hydrogen ion and filtered bicarbonate) 
into carbon dioxide and water, which diffuse into the tubular 
cells and then the peritubular capillary. Removal of the secreted 
protons by this means limits the increase in hydrogen ion 
concentration within the lumen, thereby maintaining a favor-
able gradient for continued Na + -H+ exchange. 
Given both intracellular and luminal effects of carbonic 
anhydrase, inhibition of the enzyme should diminish net 
Na + -H+ exchange. For the reasons I cited, this inhibition leads 
to a decrease in the reabsorption of both sodium bicarbonate 
and sodium chloride [33]. 
Acetazolamide is the only carbonic anhydrase inhibitor cur-
rently available for use as a diuretic [34]. One might expect that 
acetazolamide would be a potent diuretic, given that the prox-
imal tubule reabsorbs such a large fraction of the filtrate. In 
patients, however, the diuresis produced by this agent tends to 
be relatively modest and self-limited for two reasons: (1) most 
of the excess sodium delivered out of the proximal tubule can 
be recaptured in the more distal segments, particularly the loop 
of Henle, where reabsorption is largely flow-dependent; and (2) 
the diuretic action is progressively diminished by the metabolic 
acidosis that results from the loss of bicarbonate in the urine 
[34]. 
As a result, acetazolamide is primarily used in edematous 
patients with metabolic alkalosis (usually induced by a loop or 
thiazide diuretic). In this setting, the loss of sodium bicarbonate 
and sodium chloride improves both the metabolic alkalosis and 
the fluid overload. The induction of bicarbonaturia can be 
detected simply by measurement of the urine pH, which should 
rise above 7.0 when substantial amounts of bicarbonate are 
excreted. 
A similar sequence in which decreased bicarbonate reabsorp-
tion leads to diminished proximal sodium chloride reabsorption 
occurs in metabolic acidosis [35]. In this disorder, less bicar-
bonate is filtered (because of the low plasma level) and there-
fore less is available for reabsorption by Na + -H+ exchange. 
This tendency to proximal salt wasting may explain the persist-
ent hyperaldosteronism in patients with type-1 and type-2 renal 
tubular acidosis [36]. 
Secretion of diuretics. All the commonly used diuretics are 
highly protein bound and, except for spironolactone, must be 
secreted into the lumen to be effective [37]. Thus, impairment of 
secretion can interfere with diuretic responsiveness. As an 
example, animals and patients with marked hypoalbuminemia 
(plasma albumin concentration less than 1.5 g/dl) are sometimes 
relatively resistant to loop diuretics [38]. This effect might result 
from decreased drug binding in the plasma, thereby leading to a 
wider extravascular volume of distribution and a slower rate of 
delivery to the kidney. Some patients with hypoalbuminemia 
who are unresponsive either to a loop diuretic or to albumin 
infusion alone have a good diuretic response when they receive 
an infusion of protein-bound furosemide that has been prepared 
by mixing 40 mg of drug with 6.25 g of salt-poor albumin [38]. 
The efficacy of this regimen presumably is related to increased 
drug delivery to the kidney and increased secretion into the 
lumen. Finally, an additional mechanism also might contribute 
to diuretic resistance when the low albumin concentration is 
due to urinary protein losses. In this setting, free drug secreted 
into the lumen can be rendered inactive by binding to filtered 
albumin [39]. 
Loop of Henle 
Sodium entry into the cells of the medullary thick ascending 
limb of the loop of Henle occurs primarily via a Na+ -K+ -2Cl-
cotransporter (Fig. 2b), although a Na + -H+ exchanger is also 
present and contributes to bicarbonate reabsorption [40, 41]. 
This latter exchanger is somewhat more important in the 
cortical aspect of this segment, as parallel Na+-H+ and CI--
HC03 - exchangers contribute to net sodium chloride reabsorp-
tion, with hydrogen and bicarbonate recycling similar to that 
seen with hydrogen and formate in the proximal tubule (Fig. 2a) 
[41]. 
The low luminal concentration of potassium might be as-
sumed to limit Na+-K+-2CI- cotransport. This potential prob-
lem is overcome, however, by the recycling of potassium via 
potassium channels in the luminal membrane (Fig. 2b) [40]. As 
a result, reabsorbed potassium is returned to the lumen for 
continued promotion of sodium chloride transport. The sodium 
and chloride that enter the cell leave across the basolateral 
membrane via the Na + -K + -ATPase pump and selective chlo-
ride channels, respectively. 
Both the backleak of potassium across the luminal membrane 
and the transport of chloride across the basolateral membrane 
are electrogenic, creating a lumen-positive transepithelial gra-
dient. This potential is important because it can drive the 
passive paracellular reabsorption of cations, such as sodium, 
calcium and magnesium [40, 42]. As an example, the 2CI--to-
INa+ stoichiometry reduces the energy requirement for sodium 
reabsorption by 50%: for every 2 chloride ions that are reab-
sorbed, one sodium ion is actively transported out of the cell by 
the Na+-K+-ATPase pump, and one is passively reabsorbed 
between the cells [40]. 
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Fig. 4. The effect of varying luminal concentrations of sodium, potas-
sium, and chloride on the equivalent short circuit current (Is,", a 
measure of active NaCI transport) in the cortical thick ascending limb 
of the loop of Henle in the rabbit. The affinity of the Na+-K+-2CI-
transporter for sodium and potassium is very high, leading to maximum 
stimulation at low solute concentrations. In comparison, activity varies 
directly with the chloride concentration, resulting in chloride delivery 
being the rate-limiting step. (From Ref. 41.) 
Another important characteristic of Na+-K+-2Cl- cotrans-
port is that it is chloride delivery that is rate-limiting; net 
sodium chloride reabsorption varies directly with the tubular 
fluid chloride concentration (Fig. 4) [41]. The loop diuretics, 
furosemide, bumetanide, and perhaps ethacrynic acid (at least 
its cysteine adduct), decrease sodium chloride reabsorption by 
competing for the chloride site on the transporter (as evidenced 
by the ability of increasing luminal chloride to inhibit binding of 
the diuretic to the transporter) [43, 44]. The loop diuretics also 
may impair reabsorption in other nephron segments, although 
these effects probably have little physiologic importance [45, 
46]. 
Sodium chloride reabsorption in the loop of Henle is primar-
ily flow- or load-dependent, being limited mostly by the trans-
tubular concentration gradient. Sodium chloride reabsorption in 
the loop lowers the tubular fluid chloride concentration, be-
cause the ascending limb is impermeable to water [41,47]. This 
fall in chloride concentration below that of the plasma progres-
sively diminishes the activity of the Na+-K+-2Cl- transporter 
(Fig. 4) and also promotes the backleak of sodium chloride into 
the lumen across the tight junction. Eventually, the reduced 
reabsorptive flux is balanced by a backleak of equal magnitude; 
this equilibrium appears to occur at a chloride concentration of 
60 to 75 mEq/liter at the end of the cortical aspect of the thick 
ascending limb [41, 48]. 
In experimental animals, antidiuretic hormone (ADH) pro-
motes sodium chloride reabsorption in the medullary thick 
ascending limb by increasing the number of Na + -K + -2Cl-
transporters in the luminal membrane [49]. The primary conse-
quence is that total loop sodium chloride reabsorption is redis-
tributed but not increased, rising in the medulla (thereby 
enhancing the efficiency of the countercurrent mechanism) but 
falling in the cortical aspect, which cannot reabsorb chloride 
after the limiting concentration of 60 to 75 mEq/liter is reached. 
The applicability of these findings to humans is not clear, 
however. The human thick ascending limb does not appear to 
have an ADH-sensitive adenylate cyclase, although the pres-
ence of ADH receptors that might act by some other mecha-
nism cannot be excluded [50]. 
Distal tubule 
Sodium entry into the cells of the distal tubule and the 
adjacent connecting segment occurs primarily via aNa + -Cl-
cotransporter that is maximally activated when both ion binding 
sites are occupied (Fig. 2c) [51, 52]. These segments are also the 
primary site of action of the thiazide-type diuretics, which 
inhibit this carrier [43, 45], apparently by competing for the 
chloride site [52]. Microperfusion studies suggest that furo-
semide also can mildly inhibit this transporter [45]. How this 
inhibition occurs is not known, as bumetanide has no effect in 
this segment. 
Some of the thiazide-type diuretics (chlorothiazide but not 
bendroflumethiazide, for example) also mildly impair sodium 
transport in the proximal tubule because of partial inhibition of 
carbonic anhydrase [53]. This proximal effect might contribute 
to the net diuresis, although most of the excess sodium deliv-
ered out of the proximal tubule is reclaimed in the loop of 
Henle. 
Basic transport processes. The distal tubule normally reab-
sorbs about 5% of the filtered sodium. Sodium transport in this 
segment is, as in the loop of Henle, primarily flow dependent. 
Net reabsorption is limited by the maximum transtubular con-
centration gradient that can be maintained. Fluid entering the 
distal tubule has a chloride concentration of about 60 to 75 
mEq/liter; when this value is lowered to approximately 40 
mEq/liter by tubular reabsorption, further net transport ceases 
because of decreased activity of the cotransporter and backflux 
through the tight junction [51]. 
A common example of flow dependence in the distal tubule 
occurs when delivery is increased by the use of a loop diuretic. 
In this setting, there is a sustained increase in distal tubular 
reabsorption (to as much as 11% of the filtered sodium) [3, 54, 
55]; this change is accompanied by tubular hypertrophy and by 
an elevation in Na+-K+-ATPase activity, which is required to 
return the extra sodium to the systemic circulation [55-57]. As 
I will discuss later this response (which also occurs in the 
principal cells in the cortical collecting tubule [55, 57]) dimin-
ishes the net diuresis induced by loop diuretics. 
The early cortical distal nephron-the cortical thick ascend-
ing limb, distal tubule, and connecting segment-is also the site 
at which urinary calcium excretion is actively regulated [58]. 
This effect is mediated by parathyroid hormone (which stimu-
lates adenylate cyclase) and calcitriol (which increases the 
synthesis ofa calcium-binding protein); both of these hormones 
increase distal calcium reabsorption [59, 60]. How this process 
occurs is not clear [61]. It is possible that parathyroid hormone 
increases luminal calcium entry into the cell, perhaps by 
insertion of calcium channels into the luminal membrane [62]. 
Calcium entering the cell may be transported across the cell by 
the vitamin D-dependent calcium-binding protein [61] and may 
then be returned to the systemic circulation by a calcium-
ATPase or a sodium-calcium exchanger in the basolateral 
membrane [59, 60]. 
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Reabsorption of calcium at this site is independent of that of 
sodium, in contrast to the direct relationship between these two 
processes in the proximal tubule and loop of Henle. Thus, 
parathyroid hormone increases the distal reabsorption of cal-
cium without affecting that of sodium [59]. 
Diuretics and disorders of calcium balance. Diuretics can 
affect calcium excretion and are therefore effective in the 
treatment of both hypercalcemia and hypercalciuria [58]. Com-
bining loop diuretics with saline loading constitutes the initial 
therapy for hypercalcemia, as the plasma calcium is lowered by 
increasing calcium excretion in the urine. The efficacy of this 
regimen is based in part on the passive nature of calcium 
reabsorption in the medullary thick ascending limb, a site at 
which calcium traverses the paracellular route down the favor-
able lumen-positive electrical gradient created by the backleak 
of cellular potassium across the luminal membrane and into the 
lumen (Fig. 2b). In the isolated perfused tubule, for example, 
calcium reabsorption increases when the lumen-positive poten-
tial is increased and virtually ceases when the potential is 
lowered to zero [42]. A similar effect would be expected in the 
intact organism when inhibition of the Na + -K + -2Cl- trans-
porter by a loop diuretic sequentially diminishes sodium chlo-
ride uptake, potassium recycling, and the lumen-positive poten-
tial. (In comparison, calcium transport is primarily active in the 
cortical aspect of the thick ascending limb [42, 58].) 
Saline loading must accompany administration of the loop 
diuretic for maximum calciuresis to occur because calcium 
reabsorption also passively follows that of sodium and water in 
the proximal tubule. Thus, volume expansion can increase 
calcium excretion by reducing proximal sodium reabsorption. 
On the other hand, use of a loop diuretic without replacement of 
the fluid losses will stimulate proximal transport and diminish 
the calciuric effect [63]. 
The therapeutic approach to patients with recurrent calcium 
stones and idiopathic hypercalciuria is just the opposite. In 
some of these patients, a high sodium intake contributes to the 
increase in calcium excretion. Thus, one of the initial steps in 
the treatment of hypercalciuria and recurrent calcium stones is 
restriction of sodium intake [64]. If the hypercalciuria persists, 
the addition of a thiazide diuretic can lower calcium excretion 
and reduce new stone formation [65]. The hypocalciuric re-
sponse is in part due to the associated mild volume depletion, 
which increases the proximal reabsorption of sodium and water 
(in part via the generation of angiotensin II) and secondarily 
that of calcium [63]. In addition, diminishing distal sodium 
reabsorption with a thiazide diuretic increases distal calcium 
reabsorption [66]. A similar response is seen in the cortical 
collecting tubule, where a potassium-sparing diuretic reduces 
the reabsorption of sodium and increases that of calcium [66]. 
How calcium transport is increased by the distally acting 
diuretics is unclear, but two hypotheses have been proposed: an 
increase in the electrochemical gradient favoring calcium entry 
into the cell or, because the cell sodium concentration will fall 
(because ofless sodium entry), an increase in calcium exit via a 
basolateral Na + -Ca2 + exchanger [59]. The thiazide-induced 
reduction in calcium excretion also has a favorable long-term 
effect on calcium balance, as it tends to increase bone miner-
alization and reduce the incidence of hip fractures [67]. 
Collecting tubule 
Sodium is reabsorbed in both the cortical and medullary 
aspect of the collecting tubules. The cortical segment contains 
two different cell types: the principal cells that reabsorb sodium 
and secrete potassium, and the intercalated cells that are 
primarily involved in hydrogen (or bicarbonate) secretion and in 
active potassium reabsorption [68]. The luminal membrane of 
the principal cells contains sodium and potassium channels 
(Fig. 2d), not cotransporters [69, 70]; a thiazide-sensitive Na + -
Cl- cotransporter also may be present in the early cortical 
collecting tubule [71]. These cells are relatively impermeable to 
water in the basal state, but they respond to ADH by inserting 
preformed water channels into the luminal membrane [72]. 
Luminal sodium passively enters the cells through the sodium 
channels. In contrast to electroneutral Na + -K + -2CI- and Na +-
Cl- cotransport, movement through the sodium channels is 
electrogenic, creating a lumen-negative transepithelial poten-
tial. 
In states of volume depletion when the urine sodium concen-
tration can be reduced to less than 5 to 10 mEq/liter, collecting 
tubule sodium reabsorption could not occur by electroneutral 
Na + -Cl- cotransport because the luminal sodium concentration 
falls below that of the cells. In this setting, passive sodium entry 
must occur electrogenically because the cell interior negativity 
(Fig. 1) is the only driving force for passive sodium movement 
into the cell. 
The lumen-negative potential created by sodium transport 
can drive both passive chloride reabsorption via the paracellu-
lar pathway and potassium secretion from the cell into the 
lumen [73]. Sodium reabsorption also raises potassium secre-
tion by a second mechanism: the movement of reabsorbed 
sodium out of the cell by the Na+-K+-ATPase pump stimulates 
potassium entry into the cell, thereby increasing the cell pool 
available for secretion. 
The principal cells are the primary site of action of aldoste-
rone [70, 73], which also might stimulate transport in the thick 
ascending limb [73]. The primary effect of aldosterone is an 
increase in the number of open sodium channels (either by 
opening previously closed channels or by inserting new chan-
nels), thereby promoting sodium entry into the cell [73, 74]. 
Aldosterone also increases the number of open luminal potas-
sium channels and Na + -K + -ATPase activity. It is unclear, 
however, whether these latter effects result from the direct 
action of aldosterone or whether they are induced by the 
movement of sodium into the cell, which then can lead to 
increased Na + -K + -ATPase activity and a subsequent rise in the 
intracellular potassium pool [73]. 
The potassium-sparing diuretics all act at this site [43, 75]. 
Amiloride and perhaps triamterene directly block the luminal 
sodium channels, whereas spironolactone does this indirectly 
by competing with aldosterone for its cytosolic receptor. The 
net effect is a mild increase in the excretion of sodium and a fall 
in that of potassium. 
The understanding of collecting tubule function has provided 
insight into the mechanism and treatment with amiloride of the 
polyuria and polydipsia that develop in approximately 20% to 
30% of patients receiving chronic lithium therapy [76]. These 
symptoms usually are due to nephrogenic (ADH-resistant) 
diabetes insipidUS, although primary polydipsia or central 
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diabetes insipidus can be present in some patients. Lithium 
appears to act on the kidney by diminishing ADH-induced 
activation of adenylate cyclase, at least in part by decreasing 
the activity of Gs ' the stimulatory guanine regulatory protein 
[77]. For ADH resistance to occur, lithium must gain access to 
the collecting tubular cells, entering the principal cells in part 
through the luminal sodium channels. Recent studies suggest 
that blocking the sodium channels with amiloride can amelio-
rate the polyuria in patients with moderate and reversible 
disease, even if lithium administration is continued [76]. 
Sodium also is reabsorbed in the inner medullary collecting 
tubule, again entering the cells through aldosterone- and amil-
oride-sensitive sodium channels [78]. This segment is one of the 
major intrarenal sites of action of ANP [79], which is normally 
released in response to volume expansion. The binding of ANP 
to its receptor on the basolateral membrane leads to activation 
of guanylate cyclase, which comprises part of the intracellular 
domain of the ANP receptor [80]. The subsequent generation of 
cyclic GMP closes the luminal sodium channels [79] and pro-
motes excretion of the excess sodium. Atrial natriuretic peptide 
also appears to act in the cortical collecting tubule (where it 
may again close the sodium channels in the luminal membrane) 
and in the proximal tubule, perhaps via the local release of 
dopamine [26, 81]. 
Determinants of diuretic response 
I now would like to consider several aspects of diuretic 
responsiveness in humans. The clinical efficacy of a diuretic is 
related to a variety of factors, including its site and duration of 
action, its rate of excretion, dietary sodium intake, the activity 
of counterregulatory sodium-retaining mechanisms (such as the 
renin-angiotensin and sympathetic nervous systems), and di-
uretic dose [82, 83]. 
As I said, almost all the commonly used diuretics are highly 
protein bound and enter the urine primarily via the organic 
anion or cation secretory pathways in the proximal tubule [37, 
38]. Although spironolactone is also protein bound, it does not 
require access to the tubular lumen because it diffuses into the 
collecting tubule cell across the basolateral membrane and then 
binds to the cytosolic aldosterone receptor. 
Once within the lumen, the ability of loop and thiazide 
diuretics to inhibit sodium reabsorption is in part dose depen-
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Fig. 5. Dose-response curves for bumetanide 
and furosemide, relating the rate of excretion 
of the diuretic to the rate of sodium excretion . 
The solid lines represent the response of 
normal subjects to intravenous drug, whereas 
the symbols represent the response of patients 
with heart failure to oral therapy with 1 mg 
(open circles) or 2 mg (closed circles) of 
bumetanlde or to 40 mg (open triangles) or 80 
mg (closed triangles) of furosemide. Both the 
rate of diuretic excretion and response to drug 
that enters the urine is diminished in these 
disorders. (From Ref. 84.) 
dent, being determined by the rate at which the diuretic is 
delivered to its luminal site of action [82, 84]. The approximate 
dose-response curves for bumetanide and furosemide are de-
pieted in Figure 5. When a threshold level is exceeded, the 
natriuretic response increases in parallel with the rate of di-
uretic excretion, which is primarily determined by dose, until a 
maximum diuresis is seen. At this point, the diuretic-sensitive 
transporter or channel is presumably completely inhibited, and 
giving higher doses produces no further diuresis. 
In normal subjects, maximum diuresis occurs with 40 mg of 
furosemide or 1 mg of bumetanide [82]. It is of interest that oral 
and intravenous furosemide produce an equivalent effect in 
normal subjects, even though only one-half of the oral drug is 
absorbed [85]. This observation is explained by the dose-
response curves in Figure 5. Furosemide administered intrave-
nously enters the urine rapidly , and its rate of excretion (at a 
dose of 40 mg) is greater than that required for complete 
inhibition of the Na + -K+ -2Cl- transporter. Thus, a substantial 
portion of the drug is wasted in the urine. The same dose of 
furosemide administered orally results in slower urinary excre-
tion; as a result, the rate of drug excretion is mostly on the 
ascending portion of the curve in Figure 5. The net effect is a 
diuresis that is roughly equal to that obtained with intravenous 
therapy, even though total drug excretion is only about half as 
great. 
This equivalence of oral and intravenous furosemide therapy, 
however, does not apply to patients with renal insufficiency due 
to primary renal disease , cardiac failure, or hepatic cirrhosis. In 
these settings, in which renal perfusion is reduced, the intrave-
nous drug is excreted more slowly, and therefore almost all of 
it is effective. Consequently, the dose of furosemide needed for 
optimal effect when given intravenously must be doubled when 
oral therapy is substituted; failure to do so can lead to recurrent 
edema [82], as in the patient presented. This adjustment is not 
required with bumetanide, because intestinal absorption of this 
agent is almost complete. I will discuss the role of diuretic dose 
in detail momentarily. 
The response to a short-acting diuretic such as furosemide is 
depicted in Figure 6 [86, 87] . Sodium excretion increases well 
above baseline during the 6-hour period that the diuretic is 
acting, but then falls to low levels for the remainder of the day, 
because the ensuing volume depletion activates sodium-
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Fig. 6. Values for 6-hourly rates of sodium excretion in normal sub-
jects ingesting 270 mEq of sodium per day after being given 40 mg of 
furosemide. Sodium excretion rose markedly above intake (dotted line) 
during the 6-hour period after the diuretic was given, then fell well 
below intake (shaded areas) after the diuretic effect dissipated. Block-
ing the action of norepinephrine with the O!cadrenergic blocker prazosin 
and the renin-angiotensin system with captopril did not alter this 
response. (From Ref. 86.) 
retaining mechanisms. The end result in patients ingesting a 
high-sodium diet (270 mEq/day) is no net diuresis [86]. In this 
setting, persistent negative sodium and water balance can be 
achieved in one of three ways, the last of which is preferred: (1) 
The dose of furosemide can be increased, although the larger 
initial diuresis can lead to symptomatic volume depletion; (2) 
The diuretic can be given twice a day; (3) Sodium intake can be 
limited to less than 100 mEq/day. Although this limitation can 
diminish the peak diuretic effect by as much as 50% (probably 
because of the associated increase in activity of the renin-
angiotensin system) [87], a net diuresis results because the 
quantity of sodium retained when the diuretic effect has worn 
off is minimized. 
Systemic as well as intrarenal factors contribute to the 
compensatory sodium retention (also called the "braking phe-
nomenon") shown in Figure 6 [83, 88]. These factors both lower 
sodium excretion when the diuretic effect has worn off and 
progressively diminish the natriuretic response to the diuretic. 
As an example, the natriuretic response falls by as much as 40% 
by the third daily dose, depending on the degree of volume 
depletion induced [87]. 
Hypovolemia-induced increases in plasma angiotensin II, 
aldosterone, and norepinephrine levels might be expected to 
contribute to the compensatory response by stimulating proxi-
mal and collecting tubule sodium reabsorption. Blocking both 
these pathways with an angiotensin I converting enzyme inhib-
itor and an ai-adrenergic blocker, however, does not prevent 
the secondary sodium retention [86]. 
These observations do not necessarily exclude an important 
role for neurohumoral factors in the intact patient. When both 
vasoconstrictor hormones are blocked, the systemic blood 
pressure falls by a mean of 13 mm Hg because of the diuretic-
induced reduction in plasma volume [86]. Sodium excretion 
varies directly with the renal perfusion pressure via the pres-
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Fig. 7. Increment in fractional excretion of sodium (FENa) after 
intravenous furosemide and then after the addition of intravenous 
chlorothiazide (CTZ) in patients who had been treated for one month 
with furosemide (40 mg per day) (~) or placebo (El). The furosemide-
treated group had a lesser response to furosemide infusion (P < 0.05) 
and, to an equivalent degree, a greater response to the subsequent 
administration of chlorothiazide (P < 0.01). (Data from Ref. 54.) 
sure natriuresis phenomenon [89, 90]. Thus, hypotension can 
directly decrease sodium excretion. In contrast, the systemic 
blood pressure is maintained in the intact, diuretic-treated 
patient. In this situation, the compensatory decline in sodium 
excretion probably is due to the humoral stimulation of sodium 
reabsorption. 
These findings permit a more complete understanding of the 
volume regulatory actions of angiotensin II and norepinephrine. 
The combined vasoconstrictor and sodium-retaining effects of 
these hormones can, in the presence of volume depletion, 
maintain the systemic blood pressure and appropriately reduce 
sodium excretion. If, however, the tubular effects did not exist, 
prevention of hypovolemia-induced hypotension alone WOUld, 
because of pressure natriuresis, result in more urinary sodium 
loss and more pronounced volume depletion. 
Chronic diuretic therapy is associated with an additional 
intrarenal compensation. which directly impairs the peak diure-
sis. Sodium reabsorption in the distal nephron is flow depen-
dent. Chronic administration of a loop diuretic, for example, 
increases distal sodium chloride delivery and, in animals, leads 
to tubular hypertrophy, increased Na+-K+-ATPase activity, 
and increased sodium transport in the distal and cortical col-
lecting tubules [55-57]. A thiazide diuretic, on the other hand, 
acts in the distal tubule, and the anatomic and physiologic 
changes induced by increased sodium delivery are limited to the 
sodium-reabsorbing cells in the collecting tubules [91]. 
The applicability of these findings to humans is unproven, but 
a recent study provides indirect evidence that distal compensa-
tion does occur [54]. Patients with mild hypertension receiving 
no previous therapy were treated with placebo or 40 mg of 
furosemide per day for one month. Twelve hours after the last 
dose, the patients were given an intravenous infusion of furo-
semide; after a stable response was noted, an intravenous bolus 
of 500 mg of chlorothiazide was added. As Figure 7 shows, the 
group that received chronic furosemide therapy rather than 
placebo had a smaller increment in fractional excretion of 
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sodium following the test dose of furosemide (10.5% versus 
8.9%) but had a larger increment after the addition of chlorothi-
azide (7.5% versus 10.1%). These observations are consistent 
with increased sodium reabsorption at a thiazide-sensitive site 
in furosemide-treated subjects, although these findings do not 
prove that the site at which this oCcurs is the distal tubule. 
Even if a net diuresis is achieved initially, the response is 
short-lived because humoral and intrarenal compensations rap-
idly reestablish the steady state [83, 88]. This steady state is 
characterized by equal sodium intake and excretion but a 
diminution in extracellular volume due to the initial, transient 
negative sodium and water balance. This response is, of course , 
appropriate, because continued fluid losses eventually would 
lead to progressive and severe volume depletion. 
The rapidity with which the new steady state is achieved is 
often underappreciated. Assuming that diuretic dose and di-
etary sodium intake are relatively constant, negative sodium 
and potassium balance is maximal on the first day (before the 
compensatory mechanisms have been activated) and continues 
for only 3 to 9 days; after this period , intake and output are 
again equal [92]. A similar self-limited diuresis occurs in cardiac 
failure and hepatic cirrhosis. In cardiac failure , for example, the 
diuretic-induced reduction in cardiac filling pressures leads to a 
decline in cardiac output and to activation of the renin-angio-
tensin system, which prevents further fluid loss [93]. 
These observations yield an important clinical ruk: as long as 
dose, dietary intake, and renal function are stable, all the fluid 
and electrolyte complications associated with diuretics will 
occur within the first few weeks of therapy [83]. Whatever the 
values are 3 weeks after the diuretic is begun will remain stable 
over time. If, for example, the BUN and plasma creatinine, 
sodium, and potassium concentration are within the normal 
range at this time, then late volume depletion or hypokalemia is 
unlikely, and repeated blood tests at every subsequent patient 
visit are unnecessary, unless a new problem, such as vomiting 
or diarrhea, is superimposed. 
Diuretic dose. The optimal dose of a diuretic depends on the 
disease that is being treated. In essential hypertension, for 
example, the aim of therapy is to induce mild volume depletion 
while minimizing the associated electrolyte and metabolic de-
rangements. Concern about such complications has been 
heightened by recent suggestive but inconclusive evidence that 
thiazide diuretics might increase the risk of sudden death, 
particularly in patients with underlying left ventricular hyper-
trophy [94] . Hypokalemia, hyperglycemia, hyperinsulinemia, 
and hyperlipidemia all can occur and may contribute to an 
increase in cardiac risk [83, 95]. 
These observations have led many physicians to use other 
antihypertensive agents, including converting enzyme inhibi-
tors and calcium channel blockers , despite the lower cost and 
long-term experience with the thiazides. An alternative to these 
newer agents is administration of thiazide diuretics at lower 
doses than previously recommended, doses at which metabolic 
complications occur infrequently [96, 97]. Many patients with 
mild, uncomplicated essential hypertension respond as well to 
I2.5 mg of hydrochlorothiazide per day (or its equivalent) as to 
50 mg [96, 97]. Furthermore, patients already being treated with 
50 or 100 mg of hydrochlorothiazide daily often do well on a 
lower daily dose-I2.5 or 25 mg-without experiencing a rise in 
blood pressure [98, 99]. Although higher doses sometimes 
Table 2. Maximum effective doses of loop diuretics in edematous 
states 
Clinical condition Maximum dose, mg 
Furosemide Bumetanide 
IV PO IV PO 
Congestive heart failure 80-120 160-240 2-3 2-3 
Hepatic cirrhosis 40-80 80-160 1-2 1-2 
Chronic renal failure 
GFR 20-50 mllmin 80-120 160-240 2-3 2-3 
GFR <20 mllmin 160-200 320-400 8-10 8-10 
Severe acute renal failure 500 NAa 12 NA 
a NA, not applicable . 
produce more fluid loss, the antihypertensive effect may be no 
greater because of the vasoconstriction induced by activation of 
the renin-angiotensin system [96]. 
The aim of therapy is different in the edematous patient, in 
whom the dose (usually of a loop diuretic) is increased until an 
appropriate diuresis is achieved. The initial therapeutic objec-
tive is finding the single effective dose that will put the rate of 
diuretic excretion on to the ascending portion of the dose-
response curve (see Fig. 5) [82]. A patient who does not 
respond to 40 mg of furosemide in the morning should receive 
an increased single dose of 60 or 80 mg, rather than being given 
40 mg twice daily. However, some patients with marked edema 
due to cardiac failure or hepatic cirrhosis require intravenous 
therapy initially, because intestinal absorption is delayed, 
thereby diminishing the rate at which the drug is delivered to 
the kidney [84, 100]. Correction of intestinal edema and stabi-
lization of cardiac function at least partially correct this absorp-
tive defect in most patients and restore the efficacy of oral 
therapy. 
Some edematous patients are resistant to conventional doses 
of a loop diuretic; such resistance can arise from two general 
mechanisms, each of which is treated differently [82]. First, the 
rate of diuretic excretion in cardiac failure, hepatic cirrhosis, 
and renal failure can be diminished. This abnormality most 
often is due to decreased renal perfusion, but it also can result 
from impaired secretion due to severe hypoalbuminemia [38] or 
to substances that accumulate in renal failure or hepatic cirrho-
sis (such as organic anions or bile acids). The solution to this 
problem is to increase the single dose , which will raise plasma 
levels and hence increase the rate of drug delivery to the kidney 
[82]. 
The maximum effective doses of the different loop diuretics 
have been empirically derived from studies in patients with 
different edematous states. These doses, which are depicted in 
Table 2, presumably reflect the dose required to completely 
inhibit the Na+ -K + -2Cl- transporter in the thick ascending limb 
[82]. In chronic renal failure, for example, the maximum 
effective dose can be as high as 200 mg of intravenous furo-
semide in patients with advanced disease (GFR < 15 ml/min) 
[101]; even higher doses (as much as 500 mg) may be required 
in patients with oliguric acute renal failure . The dosages listed 
for cardiac failure and hepatic cirrhosis presume that the patient 
has adequate renal function; these dosages should be increased 
if concurrent renal failure is present. 
The second general mechanism of diuretic resistance is 
associated with a diminished diuretic response, even at 
346 Nephrology Forum: Diuretics 
adequate levels of drug excretion (Fig. 5) [82, 84]. This limita-
tion can result from (1) increased angiotensin II, aldosterone, 
and norepinephrine levels in cardiac failure and hepatic cirrho-
sis (which increase proximal and collecting tubule sodium 
reabsorption), (2) from flow-dependent distal tubule hypertro-
phy, leading to reabsorption of some of the excess sodium 
delivered out of the loop (Fig. 7), and (3) from the reduction in 
the number of functioning nephrons in renal failure. The net 
effect is often a partial but inadequate diuresis even though the 
Na + - K + -2CI- transporter has been completely inhibited. Thus, 
effective fluid removal sometimes requires administration of the 
diuretic two or even three times daily [82]. 
Generally, the dose ratio between intravenous furosemide 
and oral or intravenous bumetanide is 40; 1; furthermore, the 
oral furosemide dose should be twice the intravenous dose 
because of incomplete absorption (Tflble 2). The only exception 
occurs in advanced renal failure, which is associated with a 
relative increase in the extrarenal clearance of bumetanide; as a 
result, the furosemide-to-bumetanide dose ratio falls to 20; 1 
[102]. 
Resistant edema. Some patients are resistant even to high-
dose intravenous therapy with a loop diuretic given several 
times daily [82, 83]. Possible approaches to such a patient 
include the following; 
(1) A 24-hour urine collection should be obtained to estimate 
sodium excretion. If sodium excretion exceeds 100 mEq/day, 
an adequate diuresis is occurring, and the reason for persistent 
edema is excess sodium intake. A random urine specimen is 
less reliable as an indicator of sodium intake because of 
diuretic-induced alterations in the pattern of sodium excretion; 
relatively high when the drug is acting and low when the effect 
has worn off (Fig. 6). 
(2) Combination therapy can be given with a loop and a 
thiazide-type diuretic and, if necessary, a potassium-sparing 
diuretic to minimize potassium losses [103, 104]. This regimen 
has the advantage of inhibiting reabsorption at multiple sites; 
furthermore, as shown in Figure 7, the response to a thiazide 
diuretic often is increased in this setting because the distal 
tubule reabsorbs more of the filtrate when delivery is chroni-
cally increased by a loop diuretic [3, 54-57]. The major potential 
problem with this approach is that some patients have an 
exaggerated response, excreting 5 or more liters of urine and as 
much as 200 mEq of potassium daily [104]. Thus, careful 
monitoring and initial treatment with a low dose of a thiazide-
type diuretic (for example, 2.5 mg of metolazone or 25 mg of 
hydrochlorothiazide) are essential, particularly on the first day, 
when the diuresis is likely to be greatest because the neuro-
humoral compensations to fluid removal have not yet devel-
oped. 
Some clinicians prefer to use metolazone in patients with 
refractory edema, because it has been reported to be effective in 
advanced renal failure, a setting in which other thiazide-type 
diuretics are less effective [105]. The studies leading to this 
conclusion, however, used very high doses (20 to 150 mg), and 
it is likely that most thiazides will produce a similar natriuresis 
if given in equivalent doses [103]. Furthermore, only chlorothi-
azide is currently available for intravenous use. 
(3) The limiting factor in achieving an appropriate diuresis in 
some patients is a decrease in delivery of sodium chloride to the 
diuretic-sensitive sites because of the combination of a fall in 
GFR and a rise in proximal reabsorption. In isolated cases, the 
addition of either acetazolamide or corticosteroids can be 
helpful, the former by decreasing proximal transport and the 
latter by causing renal vasodilation and raising the GFR [82, 
83]. 
(4) Improving renal function and therefore diuretic respon-
siveness also can be achieved by changes in posture. Patients 
with cardiac failure and hepatic cirrhosis have renal vasocon-
striction that is exacerbated by standing. The renal vasocon-
striction is due both to pooling of blood in the lower extremities 
and to an inability in cardiac failure for the cardiac output to 
increase appropriately with exertion. In such patients, assump-
tion of the supine or legs-elevated position enhances venous 
return and maximizes cardiac output in relation to need. The 
net effect can be an increment in creatinine clearance of as 
much as 40% and a doubling of sodium excretion, both in the 
basal state and after administration of a loop diuretic [106, 107]. 
Thus, diuretic therapy may be most effective if given in the late 
afternoon or early evening, when the patient can remain supine, 
rather than in the morning when the patient is more likely to be 
erect. 
Multiple factors may be operative in some diuretic-resistant 
patients. In the patient under discussion, for example, edema 
was well controlled in the hospital, but he developed recurrent 
fluid retention after he was discharged. A rise in sodium intake, 
increased exertion and time spent in the upright position, and 
failure to double the intravenous furosemide dose when switch-
ing to oral therapy all could have played a contributory role. 
Hepatic cirrhosis. Bed rest, sodium restriction, and, if nec-
essary, spironolactone comprise the preferred initial regimen 
for fluid removal in patients with hepatic cirrhosis and ascites. 
Rapid diuresis (that is, negative fluid balance of more than 500 
ml/day) is both unnecessary and can be deleterious in patients 
who have ascites but no peripheral edema. In this setting, 
mobilization of fluid to minimize diuresis-induced plasma vol-
ume depletion can only occur across the peritoneal capillaries. 
This process is rate-limited, with a maximal transfer of 500 to 
700 mllday [108]. Paracentesis of 4 to 5 liters per day coupled 
with the administration of intravenous albumin (to minimize 
ascites reaccumulation and plasma volume depletion) is an 
alternative to bed rest and diuretic therapy in patients with 
marked ascites [109-111]. This modality, which can be per-
formed in the outpatient setting, has the advantages of being 
more predictably effective, of removing the ascitic fluid more 
rapidly, and of not leading to diuretic-induced fluid and electro-
lyte complications [109]. 
Patients with advanced hepatic cirrhosis (baseline sodium 
excretion less than 15 mEq/day) frequently have an unusual 
response to diuretics; as many as 50% are resistant to moderate 
doses ofa loop diuretic (for example, 80-160 mg of[urosemide), 
whereas almost all such patients (including those resistant to 
loop agents) respond to spironolactone in a dose of 150 to 300 
mg/day [112]. Decreased diuretic entry into the urine and 
increased reabsorption of sodium at the aldosterone-sensitive 
site might explain this paradoxical response [112, 113]. Patients 
who respond poorly to furosemide do so in part because they 
have a much lower rate of furosemide excretion despite achiev-
ing adequate plasma levels [113]. An unknown retained sub-
stance, such as bile salts, might be responsible by impairing the 
proximal organic anion secretory process, thereby limiting 
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furosemide entry into the tubular lumen. Spironolactone, on the 
other hand, might retain its efficacy because it is the only 
diuretic that does not require access to the tubular lumen; it 
enters the cell across the basolateral membrane and competes 
for the cytosolic aldosterone receptor [75]. 
Questions and answers 
DR. PAUL KURTIN (Chief, Division of Pediatric Nephrology, 
New England Medical Center, Boslon , Massachusetts): We all 
have used normal saline and furosemide to treat hypercalcemia. 
A recent review of hypercalcemia in malignancy stated that 
furosemide did very little , and that the major therapeutic effect 
was the normal saline diuresis [114] . Would you comment on 
that? 
DR. ROSE: Unfortunately, that statement was not well docu-
mented. I know of no studies that have compared the use of 
saline alone with furosemide (or another loop diuretic) plus 
saline in the treatment of hypercalcemia. In the original reports 
describing the efficacy of furosemide in this setting, therapy was 
initiated with I to 2 liters of isotonic saline; the subsequent 
addition of furosemide (plus replacement of urinary losses) led 
to a marked increase in calcium excretion [115]. The total 
diuresis often exceeded 500 mUhour, but there was no informa-
tion concerning the calciuric effect of a similar diuresis induced 
solely by saline. 
Certainly, furosemide would be of little benefit if volume 
depletion is allowed to occur because of the associated increase 
in passive calcium reabsorption in the proximal tubule [63]. If, 
however, the patient were volume expanded (because saline 
was begun before the loop diuretic), then the two modalities 
should be additive. Volume expansion alone will decrease 
proximal sodium chloride and calcium reabsorption; however, 
the ensuing increase in chloride delivery to the loop of Henle 
should result in increased sodium chloride reabsorption at this 
flow-dependent site (Fig. 4) [41] , thereby creating a more 
favorable gradient for passive calcium reabsorption [42] . The 
net effect should be a reduction in the calciuresis. Addition of a 
loop diuretic, on the other hand, will reduce net loop transport 
and should directly increase calcium excretion [63, 115]. 
We also know that loop diuretics increase calcium excretion 
in settings other than hypercalcemia. As an example, the 
ca1ciuresis following administration of a loop diuretic can lead 
to calcium stones and nephrocalcinosis in preterm infants [116] . 
Furthermore, loop diuretics can lower the plasma calcium 
concentration in patients with hypoparathyroidism in whom 
hypocalcemia cannot be prevented by causing an appropriate 
increase in the secretion of parathyroid hormone [117]. 
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Ma ssachusetts): Let me turn to 
the comment you made on "ceiling" doses of furosemide. You 
referred to Brater's work. I've been using "industrial-strength" 
furosemide for a long-time, that is , single doses of 500 to 1000 
mg. My question is: how solid are the data showing that no 
further response is obtained after you give an intravenous dose 
of 240 mg in patients with either severe acute renal failure or the 
nephrotic syndrome? 
DR. ROSE: I have no disagreement with the possible efficacy 
of very high dose therapy in acute renal failure; earlier I 
mentioned 500 mg as a maximum dose in such patients (Table 
2). Even higher doses (1000 mg over 4 hours with a total dose of 
up to 3 glday) have been given with a good diuretic effect in 
some patients with established postischemic oliguric renal 
failure [118]. This regimen, however, leads to no improvement 
in renal outcome (when compared with a control group receiv-
ing no diuretic) and is associated with an increased risk of 
ototoxicity and permanent deafness [1I8]. Therefore, I am 
somewhat leery of giving these megadoses just for fluid control 
when hemofiltration or dialysis is available. Whether therapy 
with loop diuretics within the first 12 to 24 hours of ischemia 
and oliguria might prevent the development of renal failure 
remains to be determined. 
The ceiling dose of a loop diuretic in the nephrotic syndrome 
has been less well studied than in other edematous states [82]. 
There are three potential mechanisms of diuretic resistance in 
this disorder: (1) concurrent renal insufficiency; (2) binding of 
secreted drug within the tubular lumen by filtered albumin [39, 
119]; and (3) the hypoalbuminemia-induced decrease in protein 
binding that I described before [38 , 119, 120]. Patients with a 
relatively normal plasma creatinine concentration and only 
moderate hypoalbuminemia tend to have , when compared with 
normals , both a reduced rate of furosemide excretion and a 
lesser diuretic response at a given rate of furosemide excretion 
[119, 120]. The latter effect might be due to binding by filtered 
albumin, a small decline in glomerular filtration rate, and 
increased reabsorption in other nephron segments. 
In general, the net diuretic response at a given dose is 
one-third to one-half that in normal individuals [119, 120] . This 
observation has led to an empiric recommendation that the 
ceiling dose of intravenous furosemide in nephrotic patients 
with relatively normal renal function be 80 to 200 mg [82] ; little 
data support this suggestion, however. Higher doses sometimes 
are required if the plasma albumin concentration is below 1.5 
gldl (a setting in which giving drug premixed with salt-poor 
albumin also may be effective [38]) or if the patient has renal 
insufficiency. In the latter situation, the dose should be in-
creased above that recommended for the nephrotic syndrome 
alone according to the guidelines in Table 2. Thus, the combi-
nation of intrinsic diuretic resistance associated with the ne-
phrotic syndrome and a decreased number of functioning 
nephrons can lead to a ceiling intravenous furosemide dose of 
320 to 400 mg. If this dose is ineffective, the loop diuretic can be 
given with a thiazide to block reabsorption at mUltiple sites 
within the nephron [121]. 
DR. ANDREW S. LEVEY (Division of Nephrology , N ew En-
gland Medical Center): Could you give us your view of the 
antihypertensive mechanism of thiazide diuretics? The short-
term effects are usually said to be due to volume contraction. 
The long-term effects have been attibuted to either persistent 
volume contraction or decreased resistance. 
DR. ROSE: The mechanism by which thiazide diuretics lower 
blood pressure in patients with essential hypertension is not 
completely understood. An initial diuresis with net fluid loss 
appears to be necessary but not sufficient for the hypotensive 
response. If mild hypovolemia does not occur, because of drug 
resistance or a high salt intake, blood pressure usually doesn 't 
fall , or it decreases only minimally [122, 123]. 
The blood pressure in responders begins to fall within the first 
week, but a slow decline can continue for as long as 12 weeks 
[124]. The initial hemodynamic response is mediated by a 
modest reduction in plasma volume and cardiac output [124, 
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125]. The fall in blood pressure can be minimized or even 
prevented, however, by hypovolemia-induced activation of the 
renin-angiotensin system, leading to a rise in systemic vascular 
resistance [124, 126]. 
Long-term maintenance of the antihypertensive effect is 
associated with reversal of this hemodynamic pattern: the 
plasma volume and cardiac output tend to partially return 
toward the baseline level, whereas the systemic vascular resis-
tance falls [124, 125]. Although the plasma volume can be 
nearly normal at this time, it still can be diminished in relation 
to the increased vascular capacity. The observations that the 
plasma renin activity remains elevated despite the rise in 
plasma volume, and that discontinuation of the diuretic leads to 
rapid fluid retention, are compatible with persistent arterial 
underfilling [127]. 
The mechanism responsible for the late vasodilation remains 
obscure. One hypothesis has proposed a central role for an 
endogenous digitalis-like natriuretic hormone distinct from 
ANP that acts by inhibiting the Na+-K+-ATPase pump [128, 
129]. According to this theory, diuretic-induced fluid loss di-
minishes the secretion of this hormone and leads sequentially to 
a rise in Na+-K+-ATPase activity, a fall in cellular sodium 
concentration, and increased calcium efflux from the cells; the 
decrease in cellular calcium concentration is then responsible 
for the ensuing vasodilation and reduction in vascular resis-
tance. Evaluation of this concept ultimately depends on the 
isolation of this putative hormone and determination of its 
physiologic role [130]. 
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology, 
New England Medical Center): To what extent does severe 
edema limit diuresis because of decreased absorption of the 
diuretic agent from the gastrointestinal tract? Also, to what 
extent does proteinuria prevent a diuretic from acting by virtue 
of protein binding within the tubular lumen? 
DR. ROSE: Several studies have described patients with 
marked edema who do not respond well to oral diuretic therapy 
[83, 99, 131]. Some patients, for example, are resistant to as 
much as 240 mg of oral furosemide, yet they respond well to 40 
mg given intravenously [131]. Although total drug absorption 
from the gastrointestinal tract is similar to that in normal 
individuals, the rate at which absorption occurs is diminished, 
perhaps because of intestinal edema and a decline in intestinal 
perfusion [100]. The net effects are a slower rate of drug entry 
into the lumen (with a peak value approximately half that in 
normal subjects) and a lesser diuretic response [84, 100]. These 
absorptive defects often can be corrected by fluid removal with 
intravenous diuretics and, in cardiac failure, by stabilization of 
cardiac function [100, 131]. 
I discussed the possible role of binding of the diuretic within 
the lumen, which may be as high as 75% [119]. What remains to 
be proven, however, is the exact degree to which this phenom-
enon might impair the diuretic response. Diuretic resistance is 
still evident when the increase in sodium excretion is compared 
with the rate of excretion of free (unbound) drug [119]. The 
latter determination, however, was made on the final urine. 
In-vitro studies have shown that increasing ionic strength 
reduces protein binding and substantially increases the amount 
of free drug [132]. The ionic strength in the final urine is 
generally higher than that in the thick ascending limb, so it is 
possible that more protein binds at the diuretic site of action and 
therefore inhibits diuretic efficacy more than one estimates from 
examination of the final urine [132]. 
DR. HARRINGTON: Are there any new diuretics on the hori-
zon that are substantively different from those we have now? 
Have we reached the pinnacle in our ability to diurese patients? 
DR. ROSE: Two endogenous hormones, dopamine and atrial 
natriuretic peptide (ANP), increase sodium and water excretion 
and have been studied for their potential clinical applicability. 
As I mentioned, dopamine acts primarily in the proximal tubule 
and appears to diminish both Na + -K + -ATPase activity and 
Na+-H+ exchange [25, 133]. In comparison, ANP increases 
sodium excretion both by raising the glomerular filtration rate 
and by closing the luminal sodium channels in the collecting 
tubules [78, 80, 134]. Although a dopamine infusion can pro-
duce a clinically significant diuresis, the response to infused 
ANP has generally been modest, perhaps because of the 
associated peripheral vasodilation and fall in systemic blood 
pressure [134, 135]. Possibly of greater clinical utility is inhibi-
tion of the metabolism of ANP (with an endopeptidase inhibi-
tor) and of its second messenger, cyclic GMP. In animal and in 
preliminary human studies, these compounds produce a rela-
tively large diuresis with little reduction in systemic blood 
pressure [136, 137]. 
One clinical setting in which dopamine and ANP might prove 
useful for their diuretic properties is early in the course of 
postischemic acute renal failure [133, 138]. Adequate studies in 
humans are not yet available. Animal models suggest that 
neither agent alone is protective; with ANP, the associated fall 
in blood pressure could limit its efficacy [138]. But marked 
improvement in renal function can be achieved with the com-
bination of ANP (to increase both the filtration rate and tubular 
flow) and dopamine (to prevent ANP-induced hypotension) 
[138]. 
The presence of renal hypoperfusion also might limit the 
response to ANP in advanced cardiac failure or hepatic cirrho-
sis. Patients with these disorders often have a low rate of 
sodium excretion despite marked elevations in ANP release 
[134, 139]. Increasing renal perfusion with a drug such as 
dopamine might restore the diuretic potency of ANP. For 
example, animal studies support the hypothesis that increasing 
renal perfusion pressure in these disorders can restore the 
response to ANP [140, 141]. Alternatively, either high (supra-
physiologic) doses of ANP or inhibitors of ANP or cyclic GMP 
metabolism might increase both the baseline sodium excretion 
and the response to conventional diuretics in patients with 
marked cardiac failure or hepatic cirrhosis [134, 137, 142, 143]. 
There are, to my knowledge, no important new diuretic drugs 
on the horizon. There have been new agents that are structur-
ally dissimilar to furosemide or ethacrynic acid but that still act 
in the loop of Henle. Muzolimine is one example [144]; how-
ever, neurotoxicity has limited its use. 
DR. HARRINGTON: I'm fascinated by the observation that 
proximal tubule sodium chloride reabsorption is accomplished 
using formic acid as an intermediary. How did this come about? 
What do we know about the evolutionary persistence of this 
process across species? 
DR. ROSE: I will offer a few observations on the role of 
formate, although I do not believe there is any information 
concerning how this process evolved. First, recycling of or-
ganic anions to achieve sodium chloride reabsorption is not 
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limited to the kidney. As an example, recycling of butyrate can 
be used to drive salt and water transport in the gallbladder via 
similar parallel anion and cation exchangers [145]. Second, 
chloride-formate exchange occurs in the rat and rabbit proximal 
tubule. The use of formate has a theoretical advantage over 
chloride-bicarbonate or chloride-hydroxyl exchange, both of 
which (by promoting the secretion of base) would interfere with 
net proximal bicarbonate reabsorption. Luminal chloride-bicar-
bonate exchange does occur in the proximal tubule in Necturus, 
where relatively little acidification occurs [146]. What remains 
unsettled is the quantitative contribution of chloride-formate 
exchange to net transcellular chloride reabsorption. Although 
some investigators have proposed a major role for formate [16, 
18], this is not uniformly accepted [19]. 
DR. MADIAS: Regarding your comment about calcium bal-
ance during chronic thiazide treatment, Bushinsky et al have 
shown in the rat that the chronic hypocalciuric effect of 
chlorothiazide is attended by reduced intestinal calcium absorp-
tion [147]. Have formal calcium balance studies been carried 
out in humans during chronic thiazide treatment? 
DR. ROSE: The same group has carefully studied calcium 
stone formers with idiopathic hypercalciuria [148J. As in ani-
mals, chlorthalidone decreased both urinary calcium excretion 
and intestinal calcium absorption (the latter without apparent 
change in calcitriollevels). However, the reduction in calcium 
excretion was of greater magnitude, with the net effect being the 
induction of positive calcium balance. Patients without hyper-
calciuria have not been studied as carefully. Nevertheless, the 
observations that chronic thiazide usage (usually for essential 
hypertension) is associated with increased bone density [149] 
and that the incidence of hip fracture is lower [64] are compat-
ible with positive calcium balance in these patients as well. 
DR. MADIAS: Circulatory improvement in patients with con-
gestive heart failure has been described after they were given 
diuretics but prior to the onset of diuresis. How well has a 
vasodilatory effect of diuretics been documented? 
DR. ROSE: The initial report of this phenomenon involved 
patients with acute pulmonary edema following a myocardial 
infarction [150]. In these patients, the administration of furo-
semide led to a "morphine-like" effect attended by a rise in 
venous capacitance and a fall in pulmonary capillary wedge 
pressure prior to any significant fluid loss. Subsequent studies 
in animals and humans without cardiac failure showed that this 
response appeared to originate in the kidney (it was not present 
in nephrectomized subjects on dialysis) and that it was abol-
ished by nonsteroidal antiinflammatory drugs [151, 152]. These 
observations suggested that the venodilation was mediated by a 
furosemide-induced release of vasodilator prostaglandins from 
the kidney. Local activation of the renin-angiotensin system by 
diuretic-induced inhibition of the Na + -K + -2CI- transporter in 
the macula densa might be responsible for this increase in renal 
prostaglandin production via the local generation of angiotensin 
II [153]. 
More recent studies in patients with chronic cardiac failure or 
hepatic cirrhosis have demonstrated that loop diuretics com-
monly induce an opposite effect-systemic vasoconstriction-
occurring before the diuresis and lasting for as long 2 hours 
[154, 155]. In cardiac failure, this increase in afterload often has 
deleterious hemodynamic consequences, as manifested by a fall 
in cardiac output and an elevation in pulmonary capillary wedge 
pressure [153]. The patients with cardiac failure had a high 
baseline plasma renin activity and plasma norepinephrine con-
centration; furthermore, the acute elevation in vascular resis-
tance was temporally associated with marked increases in the 
plasma levels of these vasoconstrictors [154]. 
It is not clear how one can reconcile these discrepant 
observations. Perhaps hyperplasia of the renin-secretory appa-
ratus in patients with chronic cardiac failure or hepatic cirrhosis 
leads to an exaggerated rise in renin release and subsequent 
vasoconstriction following the administration of a loop diuretic 
[154]. In comparison, the vasodilatory prostaglandin response 
might predominate in normal subjects or in patients with an 
acute myocardial infarction who do not have chronic activation 
of the juxtaglomerular apparatus. 
Reprint requests to Dr. B. Rose , Division of Nephrology, Brigham 
and Women's Hospital, 75 Francis Street, Boston, Massachusetts 
02115, USA 
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